

Table SII. Reflectance confocal microscopy evaluation parameters after ultraviolet B and A (UVB and UVA) exposition compared with unexposed skin and irradiated (irr.) unprotected skin

Parakeratosis	Spongiosis		Sunburn cells		Microvesicles		Disrupted honeycomb		Small bright epidermal cells		Dermal-epidermal junction obscuration		Non-edged dermal papillae		Enlarged dermal papillae		Blood vessel dilatation			
	Without product n (%)	With product n (%)	Without product n (%)	Non-irr. product n (%)	Without product n (%)	Non-irr. product n (%)	Without product n (%)	Non-irr. product n (%)	Without product n (%)	Non-irr. product n (%)	Without product n (%)	Non-irr. product n (%)	Without product n (%)	Non-irr. product n (%)	Without product n (%)	Non-irr. product n (%)	Without product n (%)	Non-irr. product n (%)		
SUBMED	0	34 (1.00)	36 (100)	n.s.	33 (97.1)	33 (91.7)	n.s.	34 (100)	34 (94.4)	n.s.	34 (100)	34 (94.4)	n.s.	34 (100)	34 (94.4)	n.s.	34 (100)	32 (88.9)	n.s.	
	1	0	0	1 (2.9)	1 (8.3)	0	2 (5.6)	0	0	0	5 (14.7)	8 (22.2)	0	0	2 (5.6)	0	0	4 (11.2)		
	2	0	0	0	0	0	0	0	0	0	1 (2.8)	6	6	6	6	6	6	6		
	3	0	0	0	0	0	0	0	0	0	0	6	6	6	6	6	6	6		
MED	0	34 (1.00)	29 (85.3)	0.067	33 (97.1)	21 (5.9)	0.000	34 (100)	21 (61.8)	0.000	34 (100)	13 (38.2)	0.000	29 (85.3)	2 (5.9)	0.000	34 (100)	26 (76.5)	0.005	
	1	0	4 (11.8)	1 (2.9)	20 (58.8)	0	12 (35.3)	0	0	0	0	13 (38.2)	5 (14.7)	21 (61.8)	0	8 (23.5)	0	34 (100)	17 (50)	0.000
	2	0	2 (2.9)	0	12 (35.3)	0	0	0	0	0	0	0	0	11 (32.4)	6	6	6	6	20 (58.8)	
	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
2 MED	0	34 (1.00)	24 (68.6)	0.002	33 (97.1)	0	0.000	34 (100)	8 (22.9)	0.000	34 (100)	25 (71.4)	0.010	34 (100)	3 (8.6)	0.000	29 (85.3)	0	0.000	
	1	0	10 (28.6)	1 (2.9)	15 (42.9)	0	16 (45.7)	0	6 (17.1)	0	12 (34.3)	5 (14.7)	14 (40.0)	0	14 (40.0)	0	18 (51.4)	0	24 (68.6)	
	2	0	1 (2.9)	0	17 (48.6)	0	10 (28.6)	0	3 (8.6)	0	14 (40.0)	0	17 (48.6)	6	6	6	6	6	6	
	3	0	0	3 (8.6)	0	1 (2.9)	0	1 (2.9)	0	6 (17.1)	0	4 (11.4)	6	6	6	6	6	6		
UVA 15 J	0	34 (1.00)	36 (100)	n.s.	33 (97.1)	31 (86.1)	n.s.	34 (100)	35 (97.2)	n.s.	34 (100)	36 (100)	n.s.	29 (85.3)	27 (75.0)	n.s.	34 (100)	36 (100)	n.s.	
	1	0	0	1 (2.9)	5 (13.9)	0	1 (2.8)	0	0	0	1 (2.8)	5 (14.7)	9 (25.0)	0	0	0	0	34 (100)	33 (91.7)	n.s.
	2	0	0	0	0	0	0	0	0	0	0	0	0	6	6	6	6	34 (100)	32 (88.9)	n.s.
	3	0	0	0	0	0	0	0	0	0	0	0	0	6	6	6	6	34 (100)	32 (88.9)	n.s.
UVA 20 J	0	34 (1.00)	28 (93.3)	n.s.	33 (97.1)	28 (93.3)	n.s.	34 (100)	29 (96.7)	n.s.	34 (100)	30 (100)	n.s.	29 (85.3)	24 (80.0)	n.s.	34 (100)	30 (100)	n.s.	
	1	0	2 (6.7)	1 (2.9)	2 (6.7)	0	1 (3.3)	0	0	0	0	5 (14.7)	6 (20.0)	0	0	0	0	34 (100)	29 (96.7)	n.s.
	2	0	0	0	0	0	0	0	0	0	0	0	0	6	6	6	6	34 (100)	29 (96.7)	n.s.
	3	0	0	0	0	0	0	0	0	0	0	0	0	6	6	6	6	34 (100)	29 (96.7)	n.s.
UVA 25 J	0	34 (1.00)	30 (100)	n.s.	33 (97.1)	26 (86.7)	n.s.	34 (100)	30 (100)	n.s.	34 (100)	29 (96.7)	n.s.	29 (85.3)	20 (66.7)	n.s.	34 (100)	30 (100)	n.s.	
	1	0	0	1 (2.9)	4 (13.3)	0	0	0	0	0	0	1 (3.3)	5 (14.7)	10 (33.3)	0	0	0	1 (3.3)	0	1 (3.3)
	2	0	0	0	0	0	0	0	0	0	0	0	0	6	6	6	6	6	6	
	3	0	0	0	0	0	0	0	0	0	0	0	0	6	6	6	6	6	6	

n.s.: not significant ; SUBMED: suberythematous level; MED: minimal erythema dose.